---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007834"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-10-14T12:15:14+00:00"
generated_at: "2026-10-14T12:20:05.009487+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Valion Bio touts CDMO Velocity Bioworks as Section 232 tariffs hit imports up to 100%

## Summary
- Velocity Bioworks is Valion's wholly owned CDMO in San Antonio, offering process development, analytical services and early-phase GMP drug substance manufacturing.
- Microbial GMP manufacturing at scales up to 200 liters; GMP mammalian capabilities also maintained for biologics through early clinical development.
- New Section 232 pharmaceutical framework imposes tariffs of up to 100% on certain imported patented drugs and ingredients, effective September 29, 2026.
- Velocity supports Valion's lead candidate Entolimod, in development as a potential medical countermeasure for Acute Radiation Syndrome.
- Interim CEO Dean Zikria said Valion welcomes partner discussions; no new contracts, customers or financial impact were disclosed.

## SEC filing metadata
- accession: 0001683168-26-007834
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-10-14T12:15:14+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007834/0001683168-26-007834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007834/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007834
- JSON: https://secwatch.observer/filing/0001683168-26-007834.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.